TWI267373B - Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction - Google Patents

Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction Download PDF

Info

Publication number
TWI267373B
TWI267373B TW089119671A TW89119671A TWI267373B TW I267373 B TWI267373 B TW I267373B TW 089119671 A TW089119671 A TW 089119671A TW 89119671 A TW89119671 A TW 89119671A TW I267373 B TWI267373 B TW I267373B
Authority
TW
Taiwan
Prior art keywords
antagonist
patent application
lhr
treatment
pharmaceutical composition
Prior art date
Application number
TW089119671A
Other languages
English (en)
Chinese (zh)
Inventor
Jurgen Engel
Hilde Riethmuller-Winzen
Ricardo Felberbaum
Klaus Diedrich
Wolfgang Kupker
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Application granted granted Critical
Publication of TWI267373B publication Critical patent/TWI267373B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW089119671A 1999-09-23 2000-09-22 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction TWI267373B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23

Publications (1)

Publication Number Publication Date
TWI267373B true TWI267373B (en) 2006-12-01

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089119671A TWI267373B (en) 1999-09-23 2000-09-22 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Country Status (22)

Country Link
EP (1) EP1214086A2 (enExample)
JP (2) JP2003509467A (enExample)
KR (1) KR100772852B1 (enExample)
CN (2) CN101045155A (enExample)
AU (1) AU769482B2 (enExample)
BG (1) BG66128B1 (enExample)
BR (1) BR0014198A (enExample)
CA (1) CA2383510A1 (enExample)
HK (1) HK1049117A1 (enExample)
HU (1) HUP0202741A3 (enExample)
IL (1) IL148185A0 (enExample)
MX (1) MXPA02002436A (enExample)
NO (1) NO331198B1 (enExample)
NZ (1) NZ534836A (enExample)
PL (1) PL201898B1 (enExample)
RU (1) RU2255759C2 (enExample)
SK (1) SK3752002A3 (enExample)
TR (1) TR200200738T2 (enExample)
TW (1) TWI267373B (enExample)
UA (1) UA73956C2 (enExample)
WO (1) WO2001021194A2 (enExample)
ZA (1) ZA200201374B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
ES2633453T3 (es) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
MX2020001877A (es) 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
BR112020021276A2 (pt) 2018-04-19 2021-01-26 Abbvie Inc. métodos de tratamento de sangramento menstrual intenso
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
DE69515666T2 (de) * 1994-07-22 2000-07-06 Medical College Of Hampton Roads, Norfolk VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
RU2108583C1 (ru) * 1996-07-29 1998-04-10 Николай Владимирович Рымашевский Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
EP0986550A1 (en) * 1997-06-05 2000-03-22 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
AU7779200A (en) 2001-04-24
EP1214086A2 (en) 2002-06-19
JP2003509467A (ja) 2003-03-11
HK1049117A1 (zh) 2003-05-02
CN101045155A (zh) 2007-10-03
AU769482B2 (en) 2004-01-29
HUP0202741A2 (hu) 2003-01-28
CN1376070A (zh) 2002-10-23
ZA200201374B (en) 2002-10-30
MXPA02002436A (es) 2003-02-12
JP2012051920A (ja) 2012-03-15
KR20020035879A (ko) 2002-05-15
NO331198B1 (no) 2011-10-31
KR100772852B1 (ko) 2007-11-02
CA2383510A1 (en) 2001-03-29
IL148185A0 (en) 2002-09-12
PL201898B1 (pl) 2009-05-29
NO20021430L (no) 2002-05-07
PL353244A1 (en) 2003-11-03
BG66128B1 (bg) 2011-06-30
TR200200738T2 (tr) 2002-08-21
WO2001021194A3 (en) 2002-03-14
SK3752002A3 (en) 2003-06-03
WO2001021194A2 (en) 2001-03-29
BR0014198A (pt) 2002-05-21
HUP0202741A3 (en) 2003-12-29
NZ534836A (en) 2007-07-27
UA73956C2 (en) 2005-10-17
BG106584A (bg) 2003-02-28
RU2255759C2 (ru) 2005-07-10
NO20021430D0 (no) 2002-03-21

Similar Documents

Publication Publication Date Title
ES2450592T3 (es) Uso de ulipristal para tratar los fibroides uterinos
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
ES2337129T3 (es) Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
Levy et al. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction
JP2011510949A5 (enExample)
PT1539184E (pt) Regímen de substituição de estrogénio
PT1443966E (pt) Método para a prevenção ou tratamento das doenças ginecológicas benignas
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
US20190201418A1 (en) Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
JPH04273822A (ja) 子宮内膜症の治療薬
US20080255053A1 (en) Method for the therapeutic management of endometriosis
Rabinerson et al. Membranous dysmenorrhea: the forgotten entity
Brenner The menopause
ES2320662T3 (es) Hormonoterapia restitutiva y tratamiento para la depresion con dienogest.
Barrington et al. Management of refractory pre-menstrual syndrome using subcutaneous oestradiol implants and levonorgestrel intrauterine systems
Liukko et al. Low-dose progestogens and ectopic pregnancy
Letassy et al. Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis
MacKenzie et al. Induction of labor
Sollars The Use of Estrogens
Stringer Pirfenidone and tibolone: Innovations in drug therapy for uterine fibroids
Watkinson The pharmacokinetics of drug delivery systems in hormone replacement therapy
Ahmed et al. NEW ADVANCES IN CONTRACEPTIVE METHODS
CN108853007A (zh) 一种治疗功能性子宫出血的凝胶制剂及其用途
JPH0692856A (ja) エストリオールの高血中濃度が得られる軟膏剤
HK1107262A (en) Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees